Phase II company positioned for growth

Cereno Scientific is well-positioned for strong growth in an attractive cardiovascular and rare diseases market with a diversified portfolio of clinical and preclinical candidates.


Therapeutics in rare and common cardiovascular disease

Cereno has a project portfolio targeting rare and common cardiovascular diseases. The aim is to develop treatments that can improve the quality of life and prolong the life of affected patients. The portfolio comprises a Phase II program and two preclinical programs.

Therapeutic focus

Better efficacy and fewer side effects in focus

Cardiovascular disease is the number 1 cause of death globally, killing nearly twice as many people as cancer. Cereno has an extensive experience in cardiovascular diseases and works toward the aim of developing innovative, effective and safe treatments for patients affected by rare and common cardiovascular diseases where great unmet needs persist.